DRRX - Durect Corporation

DRRX - Durect Corporation

https://www.durect.com

Recent News

Powered by Alpha Vantage

Durect Posts Narrower Loss in Fiscal Q2

Motley Fool • 1 month ago • score: -0.04

Durect ( NASDAQ:DRRX ) , a biopharmaceutical company focused on liver disease therapeutics, released results for the second quarter of fiscal 2025 on August 12, 2025. Durect posted better-than-expected earnings per share ( GAAP ) of $ ( 0.07 ) , surpassing analyst forecasts of $ ( 0.13 ) ( GAAP ) ...

Durect ( DRRX ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.14

Durect (DRRX) delivered earnings and revenue surprises of +46.15% and +39.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of DURECT Corporation ( NASDAQ: DRRX )

Benzinga • 1 month, 2 weeks ago • score: 0.22

NEW YORK, July 31, 2025 ( GLOBE NEWSWIRE ) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

Bausch Health Buys DURECT, Adds Liver Disease Drug In $63M Deal - Durect ( NASDAQ:DRRX ) , Bausch Health Companies ( NYSE:BHC )

Benzinga • 1 month, 2 weeks ago • score: 0.19

Bausch Health to acquire DURECT for $63 million upfront, plus up to $350 million in milestone payments. Phase 3 trial for AH drug larsucosterol to begin, with 90-day survival as primary endpoint. The market's back, and these 3 income stocks are thriving. See them here→ Bausch Health Companies ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

DURECT Corporation, a biopharmaceutical company, researches and develops drugs based on its epigenetic regulator and pharmaceutical programs. The company is headquartered in Cupertino, California.

52W High

$2.64

52W Low

$0.48

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.93

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.48

EV/Revenue (<3 favorable)

32.93

P/S (TTM) (<3 favorable)

35.80

P/B (<3 favorable)

17.03

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

12.22%

Institutions (25–75% balanced)

23.58%

Shares Outstanding

31,054,200

Float

27,011,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

1,657,000

Gross Profit (TTM)

4,161,000

EPS (TTM)

-0.43

Profit Margin (>10% good)

-2.10%

Operating Margin (TTM) (higher better)

-6.27%

ROE (TTM) (>15% strong)

-3.07%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.31

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—